TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37898484

Group type: EXPERIMENTAL
Intervention: Call-to-entry rate
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Contacted potential participants
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Responded to recruitment
Number of subjects: 1075
Study: 37898488

Group type: EXPERIMENTAL
Intervention: Spared mediastinal lymph node dissection
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Mediastinal lymph node dissection
Number of subjects: 1362
Study: 37898715

Group type: EXPERIMENTAL
Intervention: High myopia (HM) eyes
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Average MOSH
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Nasal MOSH
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Higher MOSH in superior direction
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Higher MOSH in inferior direction
Number of subjects: 1088
Study: 37898741

Group type: EXPERIMENTAL
Intervention: At-home, self-administered COVID-19 testing kits distributed to participants.
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Guidance on COVID-19 mitigation and health-promoting resources provided to participants.
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Toolkit for community engagement in distributing COVID-19 tests.
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Testing results from the distributed kits.
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: YMTT protocol coupled with local resourcing.
Number of subjects: 40000
Study: 37898759

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring during mechanical ventilation according to SafeBoosC treatment guideline.
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Usual care without cerebral oximetry.
Number of subjects: 3000
Study: 37898781

Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention (AEGORA) via Sidekick app with weekly prompts
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention (AEGORA) via Sidekick app with monthly prompts
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention (AEGORA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 37898978

Group type: EXPERIMENTAL
Intervention: At-home HIV/STI testing with a counselor via video chat
Number of subjects: 474

Group type: COMPARATOR
Intervention: In-person HIV/STI testing
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Stigma-focused counseling
Number of subjects: 474

Group type: COMPARATOR
Intervention: Health information counseling
Number of subjects: 474
Study: 37899137

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 163

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 163
Study: 37899143

Group type: EXPERIMENTAL
Intervention: Phone-based survey
Number of subjects: 2000

Group type: COMPARATOR
Intervention: In-person survey
Number of subjects: 2000
Study: 37899145

Group type: EXPERIMENTAL
Intervention: Maternal and fetal health and development during pregnancy
Number of subjects: 823
Study: 37899153

Group type: EXPERIMENTAL
Intervention: Interaction and learning activities (not specifically detailed in the abstract)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Caregivers' beliefs and practices regarding child development
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Caregivers' roles in child development
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Barriers to interaction and learning activities
Number of subjects: 56
Study: 37899297

Group type: EXPERIMENTAL
Intervention: Sorafenib plus triplet therapy with venetoclax, azacitidine, and homoharringtonine (VAH)
Number of subjects: 51
Study: 37899366

Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maribavir preemptive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immune-guided prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maribavir
Number of subjects: 0
Study: 37899433

Group type: EXPERIMENTAL
Intervention: High-dose pharmaceutical-grade biotin (100 mg taken orally three times a day over a maximum of 52 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose pharmaceutical-grade biotin
Number of subjects: 15
Study: 37899452

Group type: EXPERIMENTAL
Intervention: Fluorine 18
Number of subjects: 67
Study: 37899464

Group type: EXPERIMENTAL
Intervention: WM atypical development index in autistic children
Number of subjects: 191

Group type: COMPARATOR
Intervention: Subgroup comparison of WM atypical development index
Number of subjects: 191

Group type: COMPARATOR
Intervention: Threshold-free cluster enhancement-based two-sample t-test for WM microstructures
Number of subjects: 191
Study: 37899477

Group type: EXPERIMENTAL
Intervention: 8-week program of physical exercise of resistance and muscular strength (8-WVP)
Number of subjects: 0
Study: 37899481

Group type: EXPERIMENTAL
Intervention: Belatacept arm (tacrolimus, belatacept, and prednisone through day 89, then belatacept, mycophenolate mofetil, and prednisone for the remainder of year 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control arm (tacrolimus, mycophenolate mofetil, and prednisone)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Belatacept arm
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 27
Study: 37899488

Group type: EXPERIMENTAL
Intervention: Sub-Tenon anesthesia
Number of subjects: 67

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 67
Study: 37899826

Group type: EXPERIMENTAL
Intervention: IHAT (nanoparticulate iron hydroxide adipate tartrate)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: FS (ferrous sulfate)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: ASP (iron supplement)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: FS administered as a single weekly dose of 420 mg Fe
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: FS administered daily at 60 mg Fe/day
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: FS plus a micronutrient powder (MNP) administered daily at 60 mg Fe/day
Number of subjects: 246
Study: 37900149

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 180
Study: 37900564

Group type: EXPERIMENTAL
Intervention: Left atrial reservoir strain (LASr)
Number of subjects: 2712

Group type: EXPERIMENTAL
Intervention: HFA-PEFF score
Number of subjects: 2712
Study: 37900595

Group type: EXPERIMENTAL
Intervention: Anxiety group
Number of subjects: 99

Group type: COMPARATOR
Intervention: No anxiety group
Number of subjects: 99
Study: 37900725

Group type: EXPERIMENTAL
Intervention: Anodal high-definition transcranial direct current stimulation (HD-tDCS) over the ipsilesional primary motor cortex (M1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS over contralesional dorsal premotor cortex (PMd)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Anodal and cathodal HD-tDCS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 8
Study: 37900876

Group type: EXPERIMENTAL
Intervention: Conventional treatment + Dry Needling (DN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 37900953

Group type: EXPERIMENTAL
Intervention: Acute upper-body exercise in the cold
Number of subjects: 0
Study: 37901346

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 and 300 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37901358

Group type: EXPERIMENTAL
Intervention: Exercise intervention using Nordic walking poles, personalized physician exercise prescriptions, pedometers, and access to exercise videos.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exercise intervention using Nordic walking poles.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard of care (dialysis unit staff encouragement to exercise).
Number of subjects: 150
Study: 37901368

Group type: EXPERIMENTAL
Intervention: Diabetic Care App
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study: 37901478

Group type: EXPERIMENTAL
Intervention: ED PLUS
Number of subjects: 29

Group type: COMPARATOR
Intervention: CGA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 29
Study: 37901795

Group type: EXPERIMENTAL
Intervention: Active light-based 40 Hz brain stimulation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 62
Study: 37902089

Group type: EXPERIMENTAL
Intervention: H-BC (1600 mg PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-BC (800 mg PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SO (800 mg PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BC + SO (1600 mg PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BC + F (800 mg PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F (1.5 g fibre)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CON (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CON2 (placebo)
Number of subjects: 0
Study: 37902107

Group type: EXPERIMENTAL
Intervention: Sucralose- and acesulfame-potassium-containing diet soda, consumed three times daily for 1 week
Number of subjects: 0
Study: 37902144

Group type: EXPERIMENTAL
Intervention: SavvyWire guidewire
Number of subjects: 121
Study: 37902150

Group type: EXPERIMENTAL
Intervention: Physiology-based PCI (n=204)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Conventional angiography-based PCI (n=101)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR guidance (subgroup of physiology-based PCI)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Microcatheter-derived FFR guidance (subgroup of physiology-based PCI)
Number of subjects: 305
Study: 37902726

Group type: EXPERIMENTAL
Intervention: BIIB080 (10 mg every 4 weeks, 30 mg every 4 weeks, 60 mg every 4 weeks, 115 mg every 12 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: BIIB080 (60 mg every 12 weeks, 115 mg every 12 weeks) during long-term extension
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: BIIB080 (tau PET)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 37902732

Group type: EXPERIMENTAL
Intervention: Steady concentration PD with 11 g/h glucose dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Steady concentration PD with 14 g/h glucose dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Steady concentration PD with 20 g/h glucose dose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard 4-hour CAPD dwell with 2 L of 2.5% dextrose solution (control)
Number of subjects: 8
Study: 37902733

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) monitoring
Number of subjects: 492

Group type: COMPARATOR
Intervention: Site-specific usual care
Number of subjects: 492
Study: 37902744

Group type: EXPERIMENTAL
Intervention: Multilevel intervention including a decision-aid booklet personalized based on age, sex, prior screening, and comorbidity.
Number of subjects: 431

Group type: COMPARATOR
Intervention: Multilevel intervention including a screening informational booklet.
Number of subjects: 431
Study: 37902748

Group type: EXPERIMENTAL
Intervention: Nurse care management intervention including salary for a full-time OUD nurse care manager, training and technical assistance for nurse care managers, and agreement from 3 or more PC clinicians to prescribe buprenorphine.
Number of subjects: 130623

Group type: COMPARATOR
Intervention: Usual care (UC) clinics.
Number of subjects: 130623
Study: 37902777

Group type: EXPERIMENTAL
Intervention: CommunityRx intervention (low-intensity, electronic medical record-integrated social care assistance)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Usual care (admission brochure about hospital-based free food options and nonsystematic provision of resource information)
Number of subjects: 637
Study: 37902814

Group type: EXPERIMENTAL
Intervention: PAW Toolkit and telephone support calls from an occupational therapist
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual (standard support from their employer)
Number of subjects: 120
Study: 37902819

Group type: EXPERIMENTAL
Intervention: Integrated BP monitor
Number of subjects: 660

Group type: COMPARATOR
Intervention: Nonintegrated BP monitor (Control)
Number of subjects: 660
Study: 37902830

Group type: EXPERIMENTAL
Intervention: Vuse Solo ENDS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Moderate-use group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-, moderate-, and high-use groups
Number of subjects: 75
Study: 37902861

Group type: EXPERIMENTAL
Intervention: Androgen receptor signaling inhibitors (ARSi)
Number of subjects: 9
Study: 37902990

Group type: EXPERIMENTAL
Intervention: Novel anti-NRP2 antibody
Number of subjects: 0
Study: 37903112

Group type: EXPERIMENTAL
Intervention: Acupuncture at Weizhong (BL40)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acupuncture at Chize (LU5)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Moxibustion at Weizhong (BL40)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Moxibustion at Chize (LU5)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: All interventions (Acupuncture and Moxibustion)
Number of subjects: 140
Study: 37903153

Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing program
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Quality of oral hygiene
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Sugar intake
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Toothbrushing frequency
Number of subjects: 234
Study: 37903316

Group type: EXPERIMENTAL
Intervention: Risk-reducing total gastrectomy (RRTG)
Number of subjects: 126
Study: 37903324

Group type: EXPERIMENTAL
Intervention: Aspacytarabine 4.5 g/m2 per day for 6 doses
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspacytarabine in patients with secondary AML
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspacytarabine in patients with prior treatment with hypomethylating agents
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspacytarabine in patients with TP53 mutation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspacytarabine overall
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspacytarabine
Number of subjects: 65
Study: 37903325

Group type: EXPERIMENTAL
Intervention: Durvalumab before JCAR014 infusion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ongoing durvalumab therapy after JCAR014
Number of subjects: 100

Group type: COMPARATOR
Intervention: JCAR014 alone (control)
Number of subjects: 100
Study: 37903365

Group type: EXPERIMENTAL
Intervention: Cognitively enhanced tai ji quan
Number of subjects: 318
Study: 37903367

Group type: EXPERIMENTAL
Intervention: Mentored implementation of unit-based physician teams, unit nurse-physician coleadership, enhanced interprofessional rounds, unit-level performance reports, and patient engagement activities
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study: 37903440

Group type: EXPERIMENTAL
Intervention: Antibiotics administered (2,296 antibiotic regimens; 95.7% intravenous, 4.3% oral)
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed and administered on admission day
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Dosing accuracy of intravenous ciprofloxacin regimens
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Intravenous-to-oral switch
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Adult-dose tablets splitting
Number of subjects: 1867
Study: 37903465

Group type: EXPERIMENTAL
Intervention: Exogenous LH administration during ovarian stimulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low LH levels during ovarian stimulation
Number of subjects: 43
Study: 37903483

Group type: EXPERIMENTAL
Intervention: BI 690517 (3 mg, 10 mg, or 20 mg)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study: 37903504

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual viable tumor (RVT) in primary tumor (PT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathologic response assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: %RVT
Number of subjects: 0
Study: 37903568

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 76

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rituximab or Azathioprine (not specified which for this outcome)
Number of subjects: 76
Study: 37903590

Group type: EXPERIMENTAL
Intervention: Atezolizumab (adjuvant treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 37903607

Group type: EXPERIMENTAL
Intervention: 6-month SMS texting strategy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 120
Study: 37903608

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (headset with virtual reality session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (headset with no image nor audio)
Number of subjects: 0
Study: 37903679

Group type: EXPERIMENTAL
Intervention: mRNA BNT162b2
Number of subjects: 458

Group type: COMPARATOR
Intervention: AdV AZD1222
Number of subjects: 458
Study: 37903818

Group type: EXPERIMENTAL
Intervention: Preservative-free dexamethasone 0.1% eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Preserved dexamethasone 0.1% eye drops
Number of subjects: 40
Study: 37903856

Group type: EXPERIMENTAL
Intervention: Single-port robotic distal gastrectomy (SPRDG) using the da Vinci SP system
Number of subjects: 19
Study: 37903861

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 37903899

Group type: EXPERIMENTAL
Intervention: Palbociclib (median of 20 cycles)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 15
Study: 37903909

Group type: EXPERIMENTAL
Intervention: GV1001 plus gemcitabine/capecitabine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (gemcitabine/capecitabine alone)
Number of subjects: 148
Study: 37903951

Group type: EXPERIMENTAL
Intervention: Imaging-guided localization (IGL)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No IGL (Control)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both IGL and No IGL
Number of subjects: 500
Study: 37904082

Group type: EXPERIMENTAL
Intervention: 0.1% loading dose for six months followed by 0.01% for six months (N=33)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.01% for twelve months (N=32)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (vehicle for twelve months, N=32)
Number of subjects: 97
Study: 37904091

Group type: EXPERIMENTAL
Intervention: ECT (N=50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TMS (N=50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls (N=50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ECT and TMS
Number of subjects: 150
Study: 37904229

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) embedded in Tissucol Duo
Number of subjects: 6
Study: 37904241

Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg IV every 8 hours, titrated up to 5 mg if delirium persisted until ICU discharge or up to 14 days
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 37904247

Group type: EXPERIMENTAL
Intervention: TH-SC01 cells (120 million cells, single intralesional injection)
Number of subjects: 10
Study: 37904250

Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg/day for 5-7 days)
Number of subjects: 0
Study: 37904314

Group type: EXPERIMENTAL
Intervention: Seladelpar 5 or 10 mg orally once daily
Number of subjects: 106
Study: 37904861

Group type: EXPERIMENTAL
Intervention: Pain medication intake
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Total Active Motion (TAM)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: DASH scores
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pain levels
Number of subjects: 189
Study: 37905193

Group type: EXPERIMENTAL
Intervention: Isotoner™ compression gloves
Number of subjects: 73
Study: 37905356

Group type: EXPERIMENTAL
Intervention: Tablet fasted (100 mg peposertib)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tablet fed (100 mg peposertib)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OS fasted (100 mg peposertib)
Number of subjects: 12
Study: 37905421

Group type: EXPERIMENTAL
Intervention: 2-week patch monitors for AF screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37905540

Group type: EXPERIMENTAL
Intervention: B-SWELL intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wellness intervention
Number of subjects: 48
Study: 37905548

Group type: EXPERIMENTAL
Intervention: 0/1h hs-cTnI point of care (POC) instrument
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Central laboratory hs-cTnT measurements
Number of subjects: 1500
Study: 37905704

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) with xenografts
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin (I-PRF) with xenografts
Number of subjects: 36

Group type: COMPARATOR
Intervention: Xenografts alone (Control)
Number of subjects: 36
Study: 37905734

Group type: EXPERIMENTAL
Intervention: Varnimcabtagene autoleucel (var-cel)
Number of subjects: 45
Study: 37905906

Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fan-type expander (FE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both expanders (EDO and FE)
Number of subjects: 48
Study: 37906009

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Immediate Surgery
Number of subjects: 1177